Startup Dossier
Exeliom Biosciences
Paris-based clinical-stage biotechnology company developing a new generation of innate immune modulators to restore and enhance immune responsiveness in cancer, inflammatory diseases, and chronic infections. Its lead program, EXL01, is a bacterial-derived, NOD2-targeting immunomodulator that reprograms the immune microenvironment to overcome resistance and enhance immunotherapy efficacy.
About
Paris-based clinical-stage biotechnology company developing a new generation of innate immune modulators to restore and enhance immune responsiveness in cancer, inflammatory diseases, and chronic infections. Its lead program, EXL01, is a bacterial-derived, NOD2-targeting immunomodulator that reprograms the immune microenvironment to overcome resistance and enhance immunotherapy efficacy.
Structural DNA
Legal Name
Exeliom Biosciences
SIREN
824343214